RDY

Peers: VTRS TEVA AMRX ANIP AMPH ALVO PRGO OGN TAK HCM

| Held by: EMOP VWO AVEM SPEM VXUS DFEM DFAE VEU DFAX EMEQ

Index	-
Market Cap	11.05B
Enterprise Value	10.99B
Income	371.30M
Sales	3.66B
Book/sh	4.86
Cash/sh	1.03
Dividend Est.	0.08 (0.60%)
Dividend TTM	0.08 (0.63%)
Dividend Ex-Date	Jul 24, 2026
Dividend Gr. 3/5Y	-9.14% 0.00%
Payout	11.04%
Employees	27527
IPO	Apr 11, 2001

P/E	29.82
Forward P/E	22.66
PEG	2.26
P/S	3.02
P/B	2.73
P/C	12.85
P/FCF	52.00
EV/EBITDA	18.17
EV/Sales	3.00
Quick Ratio	1.39
Current Ratio	1.90
Debt/Eq	0.19
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	0.45
EPS next Y	0.59
EPS next Q	0.10
EPS this Y	-17.76%
EPS next Y	32.52%
EPS next 5Y	10.03%
EPS past 3/5Y	-4.82% 15.78%
Sales past 3/5Y	7.50% 8.27%
EPS Y/Y TTM	-44.34%
Sales Y/Y TTM	-6.76%
EPS Q/Q	-71.69%
Sales Q/Q	-14.64%
Earnings	Jul 21 AMC
EPS/Sales Surpr.	-39.87% -1.75%

Insider Own	0.00%
Insider Trans	-
Inst Own	15.34%
Inst Trans	-3.16%
ROA	6.12%
ROE	9.13%
ROIC	8.89%
Gross Margin	47.51%
Oper. Margin	10.13%
Profit Margin	10.14%
SMA20	5.42%
SMA50	7.84%
SMA200	0.51%
Trades

Shs Outstand	832.98M
Shs Float	832.67M
Short Float	3.41%
Short Ratio	9.77
Short Interest	28.39M
52W High	15.67 -15.28%
52W Low	11.36 16.86%
Volatility	1.47% 1.82%
ATR (14)	0.27
RSI (14)	68.06
Beta	0.33
Rel Volume	1.20
Avg Volume	2.91M
Volume	2,763,943

Perf Week	3.95%
Perf Month	7.06%
Perf Quarter	16.65%
Perf Half Y	3.95%
Perf YTD	-5.45%
Perf Year	-10.00%
Perf 3Y	0.23%
Perf 5Y	5.21%
Perf 10Y	44.11%
Recom	2.67
Target Price	13.19
Prev Close	13.08
Price	13.27
Change %	1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-29-26	Upgrade	Citigroup	Sell → Buy
Apr-23-26	Downgrade	Goldman	Neutral → Sell
Jun-05-25	Upgrade	HSBC Securities	Hold → Buy	$16.90
Dec-19-24	Downgrade	Nomura	Buy → Neutral
Jan-11-24	Downgrade	Jefferies	Buy → Underperform
Aug-29-23	Downgrade	HSBC Securities	Buy → Hold
May-18-23	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-17-23	Upgrade	BofA Securities	Neutral → Buy
Jan-30-23	Initiated	JP Morgan	Underweight
Nov-14-22	Downgrade	Credit Suisse	Neutral → Underperform
Jan-03-22	Resumed	BofA Securities	Neutral
Jul-27-21	Downgrade	Credit Suisse	Outperform → Neutral
Feb-02-21	Upgrade	Barclays	Equal Weight → Overweight	$56 → $70
Sep-18-20	Upgrade	Investec	Sell → Hold
Sep-18-20	Upgrade	BofA Securities	Neutral → Buy
Jan-28-20	Downgrade	CLSA	Buy → Outperform
Jan-27-20	Downgrade	CLSA	Buy → Outperform
Jan-09-20	Upgrade	Citigroup	Sell → Buy
Nov-04-19	Downgrade	BofA/Merrill	Buy → Neutral
Sep-04-19	Upgrade	Credit Suisse	Underperform → Outperform

Show Previous Ratings

Oct-12-26 03:24PM	Top Stock Reports for Oracle, American Express & Progressive (Zacks)
Aug-04-26 01:39AM	Dr. Reddys Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion, in the United States (Business Wire)
Jul-27-26 09:01PM	Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Jun-26-26 11:10AM	Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F (Business Wire)
Jun-13-26 06:22AM	Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States (Business Wire)
08:55AM	Loading…
May-29-26 08:55AM	NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY (PR Newswire)
May-16-26 03:18AM	Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada (Business Wire)
May-12-26 07:01PM	Dr Reddy's Laboratories Ltd (RDY) Full Year 2026 Earnings Call Highlights: Strategic Growth ... (GuruFocus.com) -5.18%
Apr-29-26 07:38AM	Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada (Business Wire)
Mar-05-26 03:57AM	Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's (Zacks)
Mar-04-26 09:42AM	3 Generic Drug Stocks to Watch Despite Industry Headwinds (Zacks)
Feb-20-26 10:57AM	Dr. Reddys Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept (Business Wire)
Jan-31-26 08:15AM	Coya Therapeutics to sell 2.522M shares at $4.40 in private placement (TipRanks)
Jan-25-26 08:01PM	Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
Jan-22-26 09:26AM	Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y (Zacks)
12:41PM	Loading…
Jan-21-26 12:41PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
12:14PM	Dr. Reddy's Laboratories Q3 Earnings Call Highlights (MarketBeat)
11:22AM	Doctor Reddy's: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-18-26 07:30AM	Trump in Davos, Netflix and Intel results on deck earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps up: What to watch this week (Yahoo Finance)
Jan-14-26 08:49AM	Dr. Reddys Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S. (Business Wire)
Dec-09-25 04:53AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's (Zacks)
Dec-08-25 08:23AM	3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape (Zacks)
Dec-02-25 08:00AM	Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies (Business Wire)
Nov-28-25 11:30AM	Bausch (BHC) Down 5.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Nov-07-25 11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
Oct-27-25 11:32AM	Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
11:00AM	Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
Oct-24-25 03:53PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
12:00PM	Loading…
Oct-22-25 12:00PM	Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025 (Business Wire)
Oct-09-25 08:57AM	ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering (Zacks)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-30-25 09:15AM	Here's How Alvotech is Expanding its Portfolio Beyond Immunology (Zacks)
Sep-29-25 10:04AM	Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? (Zacks)
Sep-23-25 12:19PM	Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play? (Zacks)
Sep-22-25 10:32AM	Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Sep-18-25 11:25AM	Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? (Zacks)
09:33AM	Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth (Zacks)
Sep-11-25 09:48AM	Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? (Zacks)
Sep-09-25 09:09AM	ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell? (Zacks)
Aug-18-25 08:16AM	Extrovis AG and Dr. Reddys announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. (GlobeNewswire)
Jul-30-25 10:11AM	Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-24-25 11:21AM	Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
Jul-23-25 01:57PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
01:46PM	Dr. Reddys Q1FY26 Financial Results (Business Wire)
11:20AM	Dr. Reddy's Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement (Insider Monkey)
Jul-18-25 05:08AM	New Strong Sell Stocks for July 18th (Zacks)
Jun-17-25 11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
09:15AM	Roku (ROKU) Surges 10.4%: Is This an Indication of Further Gains? (Zacks)
07:38AM	EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last? (Zacks)
Jun-05-25 08:59PM	HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold (Insider Monkey) +5.29%
11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
07:00AM	Alvotech and Dr. Reddys Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) (Business Wire)
May-12-25 05:00PM	Dr Reddy's Laboratories Ltd (RDY) Full Year 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 06:36PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
02:53PM	Dr. Reddys Q4 & Full Year FY25 Financial Results (Business Wire)
May-04-25 07:42AM	Wall Street Week Ahead (Seeking Alpha)
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
Apr-24-25 01:11PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Apr-21-25 10:23AM	Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? (Zacks)
Apr-16-25 04:38AM	Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals (Zacks)
Apr-15-25 07:15AM	3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes (Zacks)
Apr-14-25 10:13AM	Dr. Reddy's Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires (Insider Monkey)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-03-25 02:16PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Mar-31-25 09:30AM	RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar (Zacks)
Mar-27-25 11:47AM	Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara Biosimilar, and BAT2506, a Proposed Simponi Biosimilar, for Southeast Asia (PR Newswire)
Mar-19-25 11:13AM	FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review (Zacks)
Mar-18-25 08:35AM	Alvotech and Dr. Reddys Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (Business Wire)
Mar-14-25 10:45AM	Dr. Reddys announces recall of Levetiracetam 0.75% Sodium Chloride injection (TipRanks)
Mar-13-25 10:40AM	Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag (Business Wire)
Mar-01-25 02:54PM	Is Dr. Reddy's Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-27-25 08:48AM	Is Dr. Reddys Laboratories Limited (RDY) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
Feb-07-25 04:43AM	Dr Reddys and Shanghai Henlius sign agreement for HLX15 (Pharmaceutical Technology)
Feb-06-25 07:51AM	Dr. Reddys enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe (Business Wire)
06:40AM	Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. (PR Newswire)
Jan-24-25 02:03AM	Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Jan-23-25 02:02PM	Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business (Benzinga) -6.23%
01:41PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
12:35PM	Dr. Reddys Q3 & 9MFY25 Financial Results (Business Wire)
Dec-21-24 07:15AM	Dr. Reddys Laboratories Allocates Equity Shares to Employees (TipRanks)
Dec-03-24 06:52AM	Dr. Reddys Boosts Workforce with Equity Allotment (TipRanks)
Nov-30-24 04:24PM	Why Dr. Reddy's Laboratories Limited (RDY) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
06:47AM	Dr. Reddys Launches Innovative Cancer Drug in India (TipRanks)
Nov-29-24 07:34AM	Dr. Reddy's Laboratories introduces Toripalimab in India for nasopharyngeal carcinoma (Pharmaceutical Business Review)
Nov-28-24 06:15AM	Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma (Business Wire)
Nov-26-24 08:07AM	Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market (Business Wire)
Nov-20-24 08:30AM	Dr. Reddys Gains Strong Rating Amid Robust Growth (TipRanks)
Nov-07-24 06:31AM	Dr. Reddys Labs Releases Unaudited Financial Results (TipRanks)
Nov-06-24 02:15AM	Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-05-24 02:23PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
09:59AM	Dr. Reddys Q2 & H1FY25 Financial Results (Business Wire)
Oct-29-24 07:59PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Oct-25-24 07:40AM	Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year (Business Wire)
Oct-14-24 09:47AM	Dr. Reddys Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month (Business Wire)
Oct-09-24 07:57AM	Dr. Reddys Subsidiary Triumphs in CAR-T Cell Therapy Trial (TipRanks)
03:58AM	Dr. Reddys Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years (Insider Monkey)

Show Previous News

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment refers to the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Co-ChairmanMr. Gunupati Venkateswara Prasad B.E.

M.S.Mr. Kallam Satish Reddy B.Tech.

CEO & Member of the Management CouncilMr. Erez Israeli M.B.A.

CFO & Member of the Management CouncilMr. Mannam Venkatanarasimham

Global Head of IPDOMr. Krishna K. Venkatesh B.Pharma M.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Dr. Reddy's Laboratories Ltd ADR

Upgrade your Finviz experience